Eupraxia Pharmaceuticals ...

NASDAQ: EPRX · Real-Time Price · USD
5.09
-0.14 (-2.68%)
At close: Aug 26, 2025, 3:59 PM
5.32
2.90%
Pre-market: Aug 26, 2025, 08:10 AM EDT

Eupraxia Pharmaceuticals Income Statement

Financials in CAD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a 209.91K 193.27K 111.53K
Gross Profit
n/a -209.91K -193.27K -111.53K
Operating Income
-39.04K -37.2M -22.63M -20.87M
Interest Income
n/a 407.04K 569.32K 65.73K
Pretax Income
-37.01K -38.33M -23.92M -23.37M
Net Income
-36.66K -37.39M -23.26M -22.99M
Selling & General & Admin
15.71K 9.65M 5.65M 8.89M
Research & Development
23.33K 27.54M 17.2M 9.68M
Other Expenses
n/a 0.00 -0.00 n/a
Operating Expenses
39.04K 37.2M 23.2M 18.68M
Interest Expense
n/a 821.66K 1.59M 1.3M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
39.04K 37.2M 23.2M 18.68M
Income Tax Expense
n/a 48.26K 930.52K -1.34M
Shares Outstanding (Basic)
33.37K 24.15M 19.29M 14.24M
Shares Outstanding (Diluted)
33.93K 24.15M 19.29M 14.24M
EPS (Basic)
-1.1 -1.58 -1.24 -1.61
EPS (Diluted)
-1.1 -1.58 -1.24 -1.61
EBITDA
-38.66K -36.75M -22.14M -21.96M
EBIT
-38.82K -36.9M -22.33M -22.07M
Depreciation & Amortization
163.94 149.57K 193.27K 111.53K